Previous studies on blood-based biomarkers for Alzheimer’s disease suggest a less invasive blood test might be a valuable screening tool for Alzheimer-specific pathology. Pre-analytical sample storage conditions seem to play an important role on amyloid-β (Aβ) stability, impacting reliability and reproducibility. This study shows that Aβ40, Aβ42, and Aβ42/40 levels significantly and early decrease during storage at room temperature in whole blood or plasma. Storing blood samples at 4°C leads to stable Aβ peptide concentrations up to 72 h. In addition, Aβ peptides can be measured in capillary blood with a stable Aβ42/40 ratio up to 72 h at 4°C.
ZimmermannR, LelentalN, GanslandtO, MalerJM, KornhuberJ, LewczukP (2011) Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics, J Alzheimers Dis25, 739–745.
8.
VerberkIMW, SlotRE, VerfaillieSCJ, HeijstH, PrinsND, van BerckelBNM, ScheltensP, TeunissenCE, van der FlierWM (2018) Plasma amyloid as prescreener for the earliest Alzheimer pathological changes, Ann Neurol84, 648–658.
9.
OvodV, RamseyKN, MawuenyegaKG, BollingerJG, HicksT, SchneiderT, SullivanM, PaumierK, HoltzmanDM, MorrisJC, BenzingerT, FaganAM, PattersonBW, BatemanRJ (2017) Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis, Alzheimers Dement13, 841–849.
VogelgsangJ, Shahpasand-KronerH, VogelgsangR, StreitF, VukovichR, WiltfangJ (2018) Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease, Exp Brain Res236, 1241–1250.
14.
AndreazzaAC, LaksonoI, FernandesBS, TobenC, LewczukP, RiedererP, KennedySH, KapogiannisD, ThibautF, GerlachM, GalloC, KimY-K, GrünblattE, YathamL, BerkM, BauneBT (2019) Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity - a consensus of the Biomarkers Task Force from the WFSBP, World J Biol Psychiatry20, 340–351.
WillemseE, van UffelenK, BrixB, EngelborghsS, VandersticheleH, TeunissenC (2017) How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio, Alzheimers Dement13, 885–892.
17.
VandersticheleHMJ, JanelidzeS, DemeyerL, CoartE, StoopsE, HerbstV, MaurooK, BrixB, HanssonO (2016) Optimized standard operating procedures for the analysis of cerebrospinal fluid Aβ42 and the ratios of Aβ isoforms using low protein binding tubes, J Alzheimers Dis53, 1121–1132.
18.
StruyfsH, Van BroeckB, TimmersM, FransenE, SleegersK, Van BroeckhovenC, De DeynPP, StrefferJR, MerckenM, EngelborghsS (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis, J Alzheimers Dis45, 813–822.
